TLR3 and neoplasm: Some chemotherapeutics, such as anthracyclines, promote the activation of TLR3 in mouse and human tumor cells, leading to the secretion of type I IFNs, which then activate an autocrine or paracrine IFNAR­dependent circuit that drives the expression of some ISGs [32].